Skip to main content
SpringerLink
Log in

Radiopharmaceutical management of90Y/111In labeled antibodies: shielding and quantification during preparation and administration

  • Technical Notes
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Background

The combined application of potent β-emitting isotopes for therapy with γ-emitting isotopes for scintigraphy requires a profound regimen concerning team member safety and radionuclide quantification.

Methods

We have developed materials and methods for a proper and easy manipulation of90Y during preparation and administration of90Y/111In pharmaceuticals used for radioimmunotherapy.

Results

The efficacy of the shielding measures is documented. Protocols for the calibration of β-dose calibrators with respect to90Y are extended to the assessment of quench-corrected liquid scintillation counting of90Y. The contribution of90Y backscatter to111In counting is quantified. Newly developed shielding equipment allows an adequate administration of relatively large volumes (100ml) of90Y/111In labeled pharmaceuticals to patients.

Conclusions

The procedures described combine pharmaceutical (Good Manufacturing Practice) and radiation safety requirements with an accurate logging of relevant data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wiseman GA, White CA, Witzig TE, Gordon LI, Emmanoulides C, Raubitschek A, et al. Radioimmuno- therapy of relapsed non-Hodgkin’s lymphoma with Zevalin, a90Y-labeled CD20 monoclonal antibody.Clin Cancer Res 1999;5:3281s-3286s.

    PubMed  CAS  Google Scholar 

  2. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanoulides C, Raubitschek A, et al. Phase I/II trial of ZevalinTM (90yttrium ibritumomab tiuxetan; IDEC-Y2B8) radioimmunotherapy for treatment of relapsed or refractory CD20 positive B-cell non-Hodgkin’s lymphoma.J Clin Oncology 1999; 17: 3793–3803.

    CAS  Google Scholar 

  3. Juweid ME, Swayne LC, Sharkey RM, Dunn R, Rubin AD, Herskovic T, Goldenberg DM. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with131I-labeled murine and humanized anti-carcinoembryonic antigen monoclonal antibodies.Gyneco Oncol 1997; 76: 259–271.

    Article  Google Scholar 

  4. Juweid ME, Hajjar G, Swayne LC, Sharkey RM, Suleiman S, Hersko T, et al. Phase I/II trial of131I-MN-14(F(ab)2 anti- carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.Cancer 1999; 85: 1828–1842.

    Article  PubMed  CAS  Google Scholar 

  5. Sharkey RM, Goldenberg DM, Murthy S, Pinsky H, Vagg R, Pawlyk D, et al. Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14.Cancer 1993; 71: 2082–2096.

    Article  PubMed  CAS  Google Scholar 

  6. Zimmer AM. Logistics of Radioimmunotherapy with90Y Ibritumomab Tiuxetan (Zevalin).Semin Nucl Med 2004; XXXIV, 1 (Suppl): 14–19.

    Article  Google Scholar 

  7. Spies MS. Imaging and Dosing in Radioimmunotherapy with90Y Ibritumomab Tiuxetan (Zevalin).Semin Nucl Med 2004; XXXIV, 1 (Suppl): 10–13.

    Article  Google Scholar 

  8. Borghaei H, Schilder RJ. Safety and Efficacy of Radioimmunotherapy with90Y Ibritumomab Tiuxetan (Zevalin).Semin Nucl Med 2004; XXXIV, 1 (Suppl): 4–9.

    Article  Google Scholar 

  9. Zhu X. Radiation Safety Considerations with90Y Ibritumomab Tiuxetan (Zevalin).Semin Nucl Med 2004; XXXIV, 1 (Suppl): 20–23.

    Article  Google Scholar 

  10. Kossert K, Schrader H. Activity standardization by liquid scintillation counting and half-life measurement of90Y.Appl Radiat Isot 2004; 60: 741–749.

    Article  PubMed  CAS  Google Scholar 

  11. Zanzonico PB, Binkert BL, Goldsmith SJ. Bremsstrahlung radiation exposure from pure beta-ray emitters.J Nucl Med 1999; 40: 1024–1028.

    PubMed  CAS  Google Scholar 

  12. Coursey BM, Calhoun JM, Cessna JT. Radioassays of yttrium-90 used in nuclear medicine.Nucl Med Biol 1993; 20: 693–699.

    Article  PubMed  CAS  Google Scholar 

  13. Coursey BM, Collé R, Zimmerman BE, Cessna JT, Golas DB. National radioactivity standards for β-emitting radio- nuclides used in intravascular brachytherapy.Int J Radiation Oncology Biol Phys 1998; 41: 207–216.

    CAS  Google Scholar 

  14. Zimmerman BE, Cessna JT, Millican MA. Experimental determination of calibration settings for plastic syringes containing solutions of90Y using commercial radionuclide calibrators.Appl Radiat Isot 2004; 60: 511–517.

    Article  PubMed  CAS  Google Scholar 

  15. Zhu X. Radiation safety considerations with therapeutic90Y Zevalin.Health Phys 2003; 85: S31-S35.

    Article  PubMed  CAS  Google Scholar 

  16. Parker RP, Elrick RH. The assay of beta-emitting radioisotopes using Cerenkov counting.Int J Appl Radiat Isot 1996; 17: 361–362.

    Article  Google Scholar 

  17. Francois B. Detection of hard beta-emitting radionuclides in aqueous solutions using Cerenkov radiation: a review article.Int J Nucl Med Biol 1973; 1: 1–14.

    Article  PubMed  CAS  Google Scholar 

  18. L’Annunziata MF, Passo CJ. Cerenkov counting of yttrium-90 in the dry state; correlations with phosphorus-32 Cerenkov counting data.Appl Radiat Isot 2002; 56: 907–916.

    Article  CAS  Google Scholar 

  19. Van Hemert FJ, Van Lenthe H, Schimmel KJM, Van Eck- Smit BLF. Preparation, radiochemical purity control and stability of99mTc-mertiatide (Mag-3).Ann Nucl Med 2005; 19: 345–349.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Academic Medical Center, Meibergdreef 9, 1105, AZ Amsterdam, The Netherlands

    Formijn J. van Hemert, Gerrit W. Sloof, Kirsten J. M. Schimmel, Berthe L. F. van Eck-Smit & Ellinor Busemann-Sokole

  2. Departments of Oncology, Academic Medical Center, Meibergdreef 9, 1105, AZ Amsterdam, The Netherlands

    Walter L. Vervenne

Authors
  1. Formijn J. van Hemert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerrit W. Sloof
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kirsten J. M. Schimmel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Walter L. Vervenne
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Berthe L. F. van Eck-Smit
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ellinor Busemann-Sokole
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Formijn J. van Hemert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Hemert, F.J., Sloof, G.W., Schimmel, K.J.M. et al. Radiopharmaceutical management of90Y/111In labeled antibodies: shielding and quantification during preparation and administration. Ann Nucl Med 20, 575–581 (2006). https://doi.org/10.1007/BF03026825

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03026825

Key words

Search

Navigation